SCHEMBL5879160

SCHEMBL5879160

O=c1[nH]c(=O)c2c1c1[nH]c3ccc(O)cc3c1c1c(=O)[nH]c(=O)c21

nearest known ligand 0.82

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 9/20 0.82
ROCK2 O75116 5/20 0.59
SRC P12931 1/20 0.56
CDK5 Q00535 4/20 0.55
CDK5R1 Q15078 4/20 0.55
DYRK1A Q13627 2/20 0.55
GSK3A P49840 2/20 0.54
GSK3B P49841 2/20 0.54
TOP1 P11387 1/20 0.54
WEE1 P30291 3/20 0.49
MEN1 O00255 1/20 0.47
POLB P06746 1/20 0.47
GAA P10253 1/20 0.47
CASP6 P55212 1/20 0.47
KMT2A Q03164 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
PRKCA P17252 1/20 0.46
MAP3K5 Q99683 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5879153 0.79 CHEK1 (0.59) CHEK1ROCK2
SCHEMBL5879297 0.79 CHEK1 (0.59) CHEK1CDK5CDK5R1DYRK1AGSK3A
SCHEMBL5879244 0.79 CHEK1 (0.59) CHEK1CDK5CDK5R1GAA
SCHEMBL5879181 0.79 CHEK1 (0.82) CHEK1ROCK2MEN1POLBGAA
SCHEMBL5879303 0.79 CHEK1 (0.59) CHEK1ROCK2DYRK1AGSK3AGSK3B
SCHEMBL5343061 0.79 CHEK1 (0.59) CHEK1ROCK2CDK5CDK5R1DYRK1A
SCHEMBL5879238 0.76 PDGFRB (0.62) CHEK1ROCK2DYRK1AGSK3AGSK3B
SCHEMBL8120620 0.75 ROCK2 (1.00) CHEK1ROCK2SRCCDK5CDK5R1
Bis-Imide A SCHEMBL5879127 0.74 CHEK1 (1.00) CHEK1CDK5CDK5R1GSK3AGSK3B
Bis-Imide A SCHEMBL31061368 0.74 CHEK1 (1.00) CHEK1CDK5CDK5R1GSK3AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7151108-B2 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATORIES SERVIER (FR) 2006-12-19 US claimed
EP-1411057-B1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2005-04-27 EP claimed
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATOIRES SERVIER (FR) 2004-04-22 US claimed
EP-1411057-A1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2004-04-21 EP claimed
US-7151108-B2 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATORIES SERVIER (FR) 2006-12-19 US disclosed
EP-1411057-B1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2005-04-27 EP disclosed
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATOIRES SERVIER (FR) 2004-04-22 US disclosed
EP-1411057-A1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2004-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents XDH, TOP2A, TOP1 CHEK1 943/4885ROCK2 1698/4885SRC 2118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.